ArticleDiscover oncology2025
Carboxypeptidase Q(CPQ) promotes glioma progression by inducing M2 macrophage polarization and immunosuppression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correlation of AHR Activation-Induced Suppression of PWM-Stimulated IgG and IgG-Triggered Signaling in Human PBMCs.Antibodies (Basel, Switzerland) · 2026Article
- From "metabolic storm" to "immune paralysis": the dynamic evolution of macrophages and metabolism reprogramming in ARDS.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe tumor microenvironment (TME) is immunosuppressive due to the high presence of tumor-associated macrophages (TAMs). Among the different macrophage phenotypes, M2 macrophages, which are typically associated with tissue repair and immune suppression, are often the predominant form within the TME. This environment is essential for the growth and advancement of glioma. In this study, we explored whether Carboxypeptidase Q (CPQ) plays a crucial role in immune regulation of glioma by driving polarization and recruitment of M2 macrophages.
methodsMolecular and clinical data were derived from The Cancer Genome Altas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were utilized to predict the potential biological functions of CPQ. Single-cell analysis was utilized to identify the specific cell types expressing CPQ. The GSVA algorithm was employed to calculate the activity of immune suppression signaling pathways, while the CIBERSORT algorithm was used to quantify the infiltration of immune cells. The GSEA algorithm was utilized to analyze signal pathways between CPQ high- and low-expressing groups. Human glioma specimens were collected and CPQ expression was evaluated using immunofluorescence analysis.
resultsCPQ was linked to immune suppression in glioma. Elevated expression of CPQ was correlated with the increased expression of immunosuppressive checkpoints, such as PD-1, TIM-3, and CTLA-4. CPQ served as an effective gene for M2 macrophage polarization and recruitment. Furthermore, it could increase radiation resistance and operate as an independent marker of poor prognosis for glioma.
conclusionCPQ was implicated in immunosuppressive activities, and its elevated expression was associated with increased radiation resistance. Furthermore, CPQ served as an independent adverse prognostic biomarker for patients with glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.